IRCT20230501058035N2招募中2 期
Comparison of the effect of oral empagliflozin and placebo on cardiovascular function and quality of life in patients with acute myocardial infarction: a randomized, double-blind clinical trial.
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 354
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •Diagnosis of ST elevation MI acute myocardial infarction by a cardiologist based on clinical variables and ECG
- •Glomerular filtration rate (rGFR) more than 30
- •Systolic blood pressure before the first dose of the drug more than 110
- •Diastolic blood pressure before the first dose of medicine more than 70
- •The first dose of drug administration less than 72 hours after the occurrence of an acute stroke
排除标准
- •People with diabetes other than type 2
- •History of diabetic ketoacidosis
- •Hemodynamic instability caused by intravenous administration of catecholamine, calcium sensitizers, or phosphodiesterase inhibitors
- •Acute symptomatic urinary tract infection
- •Genital infection
- •Continuous treatment with SGLT2 inhibitors
- •Being treated with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin) four weeks before the screening visit.
- •Known allergy to SGLT-2 inhibitors
- •Severe hypoglycemia in the last six months treated with insulin or sulfonylurea
- •Symptomatic acute urinary tract infection (UTI) or genital infection
- •Patients currently receiving treatment with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin).
研究者
相似试验
尚未招募
3 期
Comparison of therapeutic effect of Empagliflozin (Gloripa) and Sitagliptin (Ziptin) on type 2 Diabetic patientsIRCT20200810048355N1Vice Chancellor for Research, Islamic Aazad University, Najafabad branch128
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
尚未招募
2 期
The effect of Empagliflozin on nonalcoholic fatty liver disease in non-diabetic patientson alcoholic fatty liver disease.Nonalcoholic steatohepatitis [NASH]K75.81IRCT20190122042450N1Iran University of Medical Sciences100
招募中
2 期
The cardiac effect of pioglitazone and empagliflozin among diabetic patients with NAFLDCondition 1: Nonalcoholic fatty liver disease. Condition 2: Type 2 Diabetes. Condition 3: Cardiomyopathy.Nonalcoholic steatohepatitis (NASH)Type 2 diabetesK75.81CardiomyopathyIRCT20190122042450N5Iran University of Medical Sciences70
已完成
2 期
The effect of empagliflozin on nonalcoholic fatty liver disease in diabetic patientsIRCT20190122042450N3Iran University of Medical Sciences105